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ABSTRACT
Introduction: The objective of this study was to
assess basal insulin persistence, associated
factors, and economic outcomes for
insulin-naı¨ve people with type 2 diabetes
mellitus (T2DM) in Japan.
Methods: People aged at least 18 years with
T2DM with first claim for basal insulin between
May 2006 and April 2013 (index date), no
insulin use before index date, and continuous
insurance coverage for 6 months before
(baseline) and 12 months after index date were
selected from the Japan Medical Center
Database. On the basis of whether there were
at least 30-day gaps in basal insulin treatment,
patients were classified as continuers (no gap),
interrupters (at least one prescription after gap),
and discontinuers (no prescription after gap). A
multinomial logistic regression model
identified factors associated with persistence.
Annual healthcare resource use and costs in the
year after initiation were compared between
continuers and interrupters and between
continuers and discontinuers using propensity
score-based inverse probability weighting to
adjust for baseline differences.
Results: Of the 827 people included (mean age
50 years, ca. 71% male), 36% continued, 42%
interrupted, and 22% discontinued basal
insulin therapy in the year after initiation.
Having at least one inpatient visit and using
fewer classes of non-insulin antihyperglycemic
medications during baseline were associated
with lower likelihoods of continuing therapy.
Relative to interrupters and discontinuers,
continuers had lower hospitalization rates
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[continuers, 12.7%; interrupters, 25.4%
(p\0.001); discontinuers, 28.4% (p\0.001)]
and lower inpatient costs [continuers,
¥132,013; interrupters, ¥225,745 (p = 0.054);
discontinuers, ¥320,582 (p = 0.036)], but
higher pharmacy costs [continuers, ¥158,403;
interrupters, ¥134,301 (p = 0.039);
discontinuers, ¥121,593 (p = 0.002)] in the
year after insulin initiation. Total healthcare
costs were similar for the three cohorts.
Conclusions: Substantial proportions of people
with T2DM in Japan interrupt or discontinue
basal insulin within the year after initiation,
and they have higher rates and costs of
hospitalizations than patients who continue
with their insulin therapy. Further research is
needed to understand reasons behind basal
insulin persistence and the implications
thereof to help clinicians manage T2DM more
effectively.
Funding: Eli Lilly and Company, Boehringer
Ingelheim.
Keywords: Basal insulin; Costs; Factors;
Persistence; Resource use; Type 2 diabetes
INTRODUCTION
Type 2 diabetes mellitus (T2DM), the most
common form of diabetes, affects about 7.6%
of adults aged 20–79 years in Japan [1] and
accounts for approximately 6% of the national
healthcare expenditure [2]. While much of the
estimated healthcare cost is attributable to
treatment of diabetes itself, a substantial
amount of the cost for people with T2DM is
associated with the treatment of chronic
complications arising as a result of poor
glycemic control [2]. Therefore, maintaining
adequate glycemic control among people with
T2DM is very important for the patients,
providers, and healthcare system. The
consensus-based guidelines provided by the
Japan Diabetes Society (JDS) recommend a
stepwise treatment algorithm for effective
management of T2DM [3]. According to this
algorithm, when lifestyle and diet
modifications are inadequate to maintain
glycemic control, people with T2DM initiate
treatment with an oral hypoglycemic agent
(e.g., metformin, sulfonylureas) or an
injectable (i.e., insulin or glucagon-like
peptide-1 [GLP-1] receptor agonists).
Depending on the degree of hyperglycemia,
other injectable or oral hypoglycemic agents
may subsequently be added to the regimen to
achieve adequate glycemic control [3].
Intensive insulin treatment has been shown
to be the most effective glucose-lowering
therapy; achieving good glycemic control in
turn helps prevent the development of micro-
and macrovascular complications of diabetes
[3–5]. Although insulin can help patients
achieve their glycemic targets, several studies
across multiple countries have reported
suboptimal persistence to insulin treatment
(i.e., continuous use of insulin) in the real
world. For example, in a study of a large
commercially insured insulin-naı¨ve population
in the USA, Perez-Nieves et al. found that 20%
of the patients initiating basal insulin
continued treatment in the year after
initiation without any interruption [6]. The
rates of persistence were even lower in the
second year after treatment initiation, with
only 46% of those with continuous use in the
first year also continuing use in the second year.
Similarly, Ascher-Svanum et al. found that only
20% of the people with T2DM who initiated
insulin continued treatment beyond the first
90 days after initiation [7]. Other studies have
found that the rates of persistence to basal
insulin over 1 year [8–11] or 2 years [12] in
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various countries range from 18% to 59%
among those initiating neutral protamine
Hagedorn (NPH) insulin and up to 67%
among those using insulin glargine or insulin
detemir. Particularly for Japan, in a survey of
people with diabetes (both T1DM and T2DM)
across several countries, Peyrot et al. found that
43.2% of the respondents in Japan had some
level of non-adherence to insulin treatment in
the month before the survey [13]. To the best of
our knowledge, however, no study to date has
evaluated persistence to basal insulin treatment
using real-world data in Japan.
Studies have noted that physicians,
including those in Japan, are reluctant to
initiate insulin treatment for several reasons
including physicians’ perception that patients
will not be willing to initiate and continue
treatment as prescribed [13, 14]. As such, a
better understanding of the characteristics of
persistent versus non-persistent people in Japan
is needed, as having such information can help
clinicians manage the care for their patients
more effectively. Furthermore, the importance
of patients continuing on their prescribed
medication has been demonstrated in several
studies in the USA which found that
discontinuation of insulin therapy is
associated with increased use of acute medical
care services (e.g., hospitalizations) and costs
compared with those continuing the treatment
as prescribed [6, 7, 10, 15]. However, the
implications of basal insulin persistence
among the Japanese population remain to be
explored.
Therefore, the goal of the present study was
to provide a better understanding of basal
insulin persistence, specifically with regards to
treatment continuation, interruption, and
discontinuation within a year of insulin
initiation among people with T2DM in Japan
using de-identified administrative health
insurance claims data. In addition, the study
aimed to assess the factors associated with
continuation, interruption, and
discontinuation of basal insulin use in the
year after treatment initiation and the
implications of the different persistence
patterns for healthcare resource use and costs
during the year after treatment initiation.
METHODS
Data and Sample Selection
De-identified administrative claims from Japan
Medical Data Center, a database containing
information on medical and pharmacy services
provided between May 1, 2005 and April 30,
2014 for approximately 2 million beneficiaries
(persons aged less than 70 years who are
employed by middle-to-large size companies in
Japan and their dependents), were used for this
analysis [16, 17]. The population of interest
consisted of beneficiaries with T2DM who had
at least one pharmacy claim for basal insulin
(insulin glargine, insulin detemir, NPH insulin,
insulin degludec) between May 1, 2006 and
April 30, 2013. The date of the first pharmacy
claim for basal insulin during this time period
was defined as the index date, the 6-month
period prior to the index date as the baseline
period, and the 12-month period following the
index date as the follow-up period. Beneficiaries
were identified as having T2DM if they met any
of the following conditions: (1) at least two
diagnoses for T2DM (ICD-10 code E11.x or
E14.x) and fewer diagnoses for type 1 diabetes
(ICD-10 code E10.x) in the 18-month period
comprising the baseline and follow-up periods
(‘‘observation period’’), OR (2) at least one
diagnosis of T2DM during the observation
period and at least one prescription for
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non-insulin antihyperglycemic medication in
the 6-month baseline period (an approach
consistent with previous research [18, 19]).
Further, beneficiaries were required to be at
least 18 years old, have no indication of any
insulin use (including mixtures and mealtime
insulin) in the 6 months prior to and including
the index date, and no indication of secondary/
other diabetes (ICD-10 codes E08.x, E09.x,
E13.x), pregnancy (including gestational
diabetes; ICD-10 codes O00.x–O08.x,
O10.x–O16.x, O20.x–O29.x, O30.x–O48.x,
O60.x, O75.x, O80.x–O92.x, O94.x–O99.x,
Z32.1, Z33.x-Z35.x, Z37.x, Z39.x) throughout
the baseline and follow-up periods. Beneficiaries
were also required to have continuous
enrollment in health plans throughout the
observation period (to ensure availability of
complete pharmacy and medical care
information) to be included in the final
analytic sample.
This article is based on previously collected
data, and does not involve any new studies of
human or animal subjects performed by any of
the authors.
Basal Insulin Persistence
Availability of the days’ supply for each basal
insulin claim was necessary to assess persistence
to treatment. However, this information was
not directly available from the data; it was
derived from the dates of prescriptions using
the following approach. First, the median
number of days between prescriptions was
calculated for the entire sample. Given that
the days’ supply may differ as a function of the
quantity prescribed, the median days were
calculated separately for basal insulin claims
with 300 units (median 29 days, 25th percentile
26 days, 90th percentile 56 days) and 600 units
or more (median 35 days, 25th percentile
28 days, 90th percentile 63 days) of insulin
administered (no dosages that were between
300 and 600 units were observed in the data).
Next, for each pair of consecutive claims, the
days’ supply were computed as the minimum of
the number of days until the patient’s next
basal insulin claim and the median number of
days between consecutive basal insulin claims
observed for the entire sample.
Given the variability in insulin doses,
persistence was defined allowing for a grace
period (or gap) in available days’ supply of basal
insulin. There are two commonly used
approaches in the literature to define the
maximum allowable gap in treatment: (1) less
than 30 days between two consecutive refills
[6–8], and (2) time between refills that is less
than the 90th percentile of the duration
between consecutive basal insulin prescription
fills for the sample [9, 10, 15]. In this sample,
both approaches resulted in similar gap lengths.
For the core analyses, the maximum allowable
gap in days’ supply was 30 days and the final
analytic sample was stratified into three
mutually exclusive groups: (1) continuers or
persistent users—no gaps of 30 days or more in
basal insulin supply during the first 12 months,
(2) interrupters—those with at least one basal
insulin claim after the first at least 30-day gap in
supply of basal insulin during the year after
treatment initiation (independent of whether
they subsequently discontinued treatment),
and (3) discontinuers—those with no basal
insulin claims after the first at least 30-day gap
in supply of basal insulin during the year after
treatment initiation. As a sensitivity analysis,
persistence was evaluated allowing for a gap
that was less than the 90th percentile of the
duration between consecutive basal insulin
prescription fills for the sample (see
‘‘Sensitivity Analyses Involving Definition of
Basal Insulin Persistence’’ and ‘‘Sensitivity
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Analyses’’). During the follow-up period, basal
insulin therapy could be the same type as index
insulin or other basal insulin or premixed
insulin.
In order to better characterize basal insulin
use among the interrupters, the number and
duration of gaps during the 1-year follow-up
period were estimated. Note, it is possible that a
patient with at least one interruption
subsequently discontinued treatment during
the 1-year follow-up period. For the purpose of
this analysis, the discontinuation of treatment
was considered as another ‘‘gap’’ in treatment
and the duration of this ‘‘gap’’ was truncated at
the end of the 1-year follow-up period.
Time to first interruption, defined as the
time between basal insulin initiation and the
day prior to the first at least 30-day gap in the
supply of basal insulin, was estimated using
Kaplan–Meier analyses. Data for discontinuers
were censored at the time of first
discontinuation. A similar analysis was
conducted to estimate time to
discontinuation, with data for interrupters
censored at the time of first interruption.
Baseline Characteristics
Differences in demographics (mean age and
gender), type of basal insulin used at treatment
initiation (analogue vs. human), mode of index
basal insulin delivery (i.e., pen or cartridges),
Charlson comorbidity index (CCI) [20], and
presence of microvascular and macrovascular
comorbidities, depression, obesity, other
neurological disorders, hypoglycemic events,
or dementia during the 6-month baseline
period were separately evaluated between
continuers and interrupters and between
continuers and discontinuers. In addition,
measures of medical resource use (likelihood
of inpatient and outpatient visits and number
of inpatient and outpatient days) as well as
prescription drug use (antihyperglycemic
medication use: overall and by class of
medication; number of unique classes used,
proportions using antihypertensives, statins,
antidepressants, or antiplatelet agents) during
the baseline period were compared across
cohorts. Statistical significance of differences
was evaluated using Chi-squared tests for
categorical variables and Wilcoxon rank-sum
tests for continuous variables. Statistical
significance was defined as p\0.05.
Outcomes and Statistical Analyses
Factors Associated with Basal Insulin
Persistence
Factors associated with basal insulin
interruption and discontinuation were
identified using a multinomial logistic
regression model (with continuous use as the
reference category). All patient characteristics
evaluated during the 6-month period prior to
basal insulin treatment initiation and at index
date (as described above), excluding
comorbidities with less than 3% prevalence,
were considered as potential factors associated
with basal insulin persistence.
Medical Resource Use and Costs Associated
with Basal Insulin Persistence
Annual medical resource use stratified by place
of service (i.e., inpatient, outpatient) as well as
antihyperglycemic medication use in the year
after initiation was compared between
continuers and interrupters and between
continuers and discontinuers. Both all-cause
resource use and diabetes-related resource use
(defined as claims with ICD-10 codes E11.x or
E14.x) were evaluated. In addition, all-cause
and diabetes-related medical, pharmacy, and
total healthcare costs were compared across the
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cohorts of interest. Diabetes-related costs
included costs associated with diabetes-related
medical claims and antihyperglycemic
prescription medications.
Differences in underlying characteristics
were accounted for using a propensity
score-based inverse probability weighting
(IPW) method [21]. As with other propensity
score-based approaches, the propensity (i.e.,
likelihood) of being in a given cohort as a
function of observed baseline characteristics
was estimated using a multinomial logistic
regression model. Select baseline and index
date characteristics were included as potential
independent covariates. Following the
computation of propensity scores, each person
was attributed a weight defined as the inverse of
the propensity score for that person. The
weighted baseline characteristics were
evaluated to ensure that no important
differences remained across cohorts. Statistical
comparisons were made between continuers
and interrupters and between continuers and
discontinuers using weighted t tests for
continuous measures and weighted
Chi-squared tests for categorical variables.
Finally, the medical/prescription drug-related
resource use and cost outcomes were compared
between continuers and interrupters and
between continuers and discontinuers using
similar statistical tests as described above.
Medication Use During the First Gap
in Treatment
The proportions of interrupters and
discontinuers using the various classes of
antihyperglycemic medications during the first
gap in treatment were evaluated. For
discontinuers, this metric was evaluated for
the time period between the start of the gap
and end of the follow-up period. Prescriptions
filled prior to the start of the first gap but with
days of supply that overlapped with the gap
were included. No comparisons were made
within or between the cohorts.
Sensitivity Analyses Involving Definition
of Basal Insulin Persistence
Two factors may potentially affect the rates of
persistence to basal insulin within this
population: (1) the lack of actual days of
supply associated with basal insulin claims in
the data, and (2) high degree of variability in
patient-specific dosing of insulin. Therefore, as
a sensitivity analysis, the study estimated the
proportions of patients characterized as
continuers versus interrupters or discontinuers
in the first year after treatment initiation,
allowing for gaps of up to 60, 90, and 120 days
between available days’ supply for basal insulin.
In addition, the study estimated persistence
patterns using an alternative definition of
persistence that has been used in the literature
[9, 10, 15], i.e., allowing for time between refills
that is less than the 90th percentile of the
duration between consecutive basal insulin
prescription fills for the sample, stratified by




A total of 827 people were included in the final
analytic sample (Fig. 1). During the first year
after treatment initiation, 36% of the people
used basal insulin continuously, 42% had at
least one gap of 30 days or more between
prescriptions, and 22% discontinued therapy
after the first gap of at least 30 days (Fig. 2).
During the 1-year follow-up period, interrupters
had on average 1.9 gaps, with a mean duration
of 60.8 days per gap. In regard to timing of
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interruption, approximately half of the
interrupters had their first gap in therapy
within the first 90 days following treatment
initiation. Based on the Kaplan–Meier analysis
that adjusted for censoring, the estimated
probability of interruption within 3 months
Fig. 1 Sample selection and resulting patient counts.
Non-mixed basal insulins are insulin detemir, insulin
glargine, NPH (neutral protamine Hagedorn) insulin, and
insulin degludec; T2DM was identiﬁed using ICD-10 codes
E11.x and E14.x; T1DM was identiﬁed using ICD-10 codes
E10.x, secondary diabetes as ICD-10 codes E08.x–E09.x,
E13.x, and pregnancy as ICD–10 codes O00.x–O08.x,
O10.x–O16.x, O20.x–O29.x, O30.x–O48.x, O60.x–O75.x,
O80.x–O92.x, O94.x–O99.x, Z32.1, Z33.x–Z35.x, Z37.x,
Z39.x
Fig. 2 Basal insulin persistence patterns in the year after treatment initiation. Early interruption and early discontinuation
deﬁned as having the ﬁrst gap in insulin therapy within the ﬁrst 90 days of treatment initiation
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was 23% (Fig. 3). Among the discontinuers, 54%
discontinued basal insulin within the first
90 days of treatment initiation. In the
Kaplan–Meier analysis, there was a 13%
probability that patients discontinued basal
insulin within 3 months after initiation (Fig. 3).
Baseline Characteristics
People using basal insulin continuously were
older (51 years vs. 50 years for interrupters and
49 years for discontinuers) (Table 1). In
addition, continuers were more likely to have
a diagnosis of hypertension or dyslipidemia,
used more classes of non-insulin
antihyperglycemic medications, and were less
likely to use inpatient medical services but more
likely to use outpatient medical services in the
6-month baseline period relative to the other
two cohorts (Table 1). Within each cohort,
75–77% of people initiated treatment with
insulin glargine, 14–18% with insulin detemir,
6–9% with NPH insulin, and 0–1% with insulin
degludec. In addition, most (94%) patients,
Fig. 3 Kaplan–Meier estimates of time to treatment
interruption (top) and discontinuation (bottom). When
assessing time to interruption, discontinuers were censored
at the time of discontinuation. Similarly, when assessing
time to discontinuation, interrupters were censored at the
time of ﬁrst interruption
156 Diabetes Ther (2017) 8:149–166








[A] [B] [A vs. B] [C] [A vs. C]
Demographics
Age on index date, mean (SD) 50.8 (9.5) 49.5 (9.9) 0.086 48.7 (10.4) 0.019*
Gender (male), % 69.6 70.8 0.737 73.2 0.399
Mode of delivery of index basal insulin, %
Pen 92.0 95.1 0.100 95.5 0.132
Cartridge 8.0 4.9 0.100 4.5 0.132
Index basal insulin, %
Insulin glargine 76.9 75.4 0.642 76.5 0.923
Insulin detemir 14.0 18.1 0.168 14.5 0.885
NPH 7.7 5.7 0.317 8.9 0.630
Insulin degludec 1.3 0.9 0.709 0.0 0.302
Index year, %
2006 (May–December) 2.3 1.4 0.392 0.6 0.268
2007 1.7 1.1 0.739 0.6 0.418
2008 7.0 5.2 0.319 3.9 0.161
2009 14.7 17.8 0.295 8.9 0.065
2010 17.7 19.5 0.567 17.3 0.910
2011 19.1 18.6 0.887 29.6 0.008*
2012 27.8 25.8 0.572 29.1 0.762
2013 (January–April) 9.7 10.6 0.705 10.1 0.899
Select comorbidities, %
Retinopathy 0.3 1.1 0.381 2.2 0.068
Diabetic foot 0.3 0.3 1.000 0.0 1.000
Nephropathy 8.0 8.3 0.896 8.9 0.728
Hypertension 50.8 44.4 0.103 34.1 \0.001*
Dyslipidemia 69.6 60.2 0.013* 53.1 \0.001*
Cardiovascular disease 19.1 21.5 0.445 16.2 0.430
Congestive heart failure 9.0 15.5 0.013* 10.6 0.570
Peripheral vascular disease 15.1 16.3 0.655 15.1 0.992
Stroke 11.0 12.6 0.538 10.6 0.886
Depression 8.4 4.6 0.049* 4.5 0.104
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independent of the cohort, used a basal insulin
pen at the time of treatment initiation (Table 1).
Factors Associated with Treatment
Interruption and Discontinuation
Multivariable models indicated that having at
least one hospital visit prior to basal insulin
initiation was associated with significantly
higher likelihoods of treatment interruption
and discontinuation. Use of multiple classes of
antihyperglycemic medications was associated
with significantly lower likelihoods of
treatment interruption and discontinuation. In
addition, presence of congestive heart failure
was associated with significantly higher
likelihood of treatment interruption, while
presence of cardiovascular disease (not
congestive heart failure) and other
neurological disorders was associated with
significantly lower likelihood of treatment
discontinuation (Table 2).
Follow-up Period Outcomes
Although the three cohorts differed in terms of
several of the baseline characteristics evaluated,
including age, medical resource use measures,
and prescription drug use measures, the inverse
probability weighting resulted in cohorts with
similar characteristics (Table S1 in the
supplementary information). After we
accounted for underlying differences,









[A] [B] [A vs. B] [C] [A vs. C]
Obesity 3.0 1.7 0.276 1.1 0.223
Other neurological disorders 6.7 4.6 0.244 3.9 0.203
Hypoglycemic event 3.0 2.6 0.739 3.4 0.836
Dementia 0.7 0.6 1.000 0.0 0.531
CCI, mean (SD) 2.8 (2.1) 3.2 (2.6) 0.151 2.9 (2.4) 0.950
Medical resource use (% with C1 visit)
Inpatient 20.4 30.4 0.004* 36.3 \0.001*
Outpatient 98.3 97.7 0.575 95.0 0.035*
Primary care visits, mean (SD) 4.7 (2.4) 3.8 (2.4) \0.001* 3.3 (2.5) \0.001*
Non-insulin antihyperglycemic prescription use
Number of unique classes, mean (SD) 2.5 (1.4) 2.1 (1.5) \0.001* 1.3 (1.5) \0.001*
At least one prescription ﬁll, % 87.0 79.7 0.014* 52.0 \0.001*
Any oral antihyperglycemic drug 87.0 79.7 0.014* 52.0 \0.001*
Any injectable 6.7 2.6 0.012* 2.8 0.064
CCI Charlson comorbidity index, NPH neutral protamine Hagedorn, SD standard deviation
* Statistically signiﬁcant at p\0.05; P values estimated relative to continuers cohort using Chi-squared tests for categorical
variables and Wilcoxon rank-sum tests for continuous variables
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(2.2 ± 7.8 vs. 4.9 ± 15.6 for interrupters and
6.5 ± 17.6 for discontinuers) in the year after
treatment initiation compared with interrupters
and discontinuers (Table 3). Consequently,
continuers had lower hospital-related costs
than interrupters and discontinuers (¥132,013
Table 2 Factors associated with treatment interruption and discontinuation relative to continuation in the year after
initiation
Parameter Interruption Discontinuation
OR (95% CI) OR (95% CI)
Demographics
Age on index date 0.99 (0.97, 1.01) 1.00 (0.98, 1.03)
Gender (male) 1.11 (0.77, 1.59) 1.19 (0.75, 1.89)
Analogue basal insulin at index 1.44 (0.69, 3.00) 0.74 (0.32, 1.75)
Using cartridges for initiating basal insulin 0.56 (0.28, 1.11) 0.45 (0.18, 1.13)
Select comorbidities
Nephropathy 1.19 (0.64, 2.18) 1.07 (0.50, 2.30)
Hypertension 0.83 (0.59, 1.17) 0.68 (0.44, 1.07)
Dyslipidemia 0.75 (0.52, 1.07) 0.79 (0.50, 1.23)
Cardiovascular disease 0.85 (0.53, 1.35) 0.49 (0.26, 0.91)*
Congestive heart failure 1.87 (1.08, 3.23)* 1.34 (0.65, 2.74)
Peripheral vascular disease 1.06 (0.65, 1.73) 1.00 (0.53, 1.88)
Stroke 0.96 (0.55, 1.68) 0.85 (0.41, 1.75)
Depression 0.73 (0.35, 1.55) 0.84 (0.31, 2.22)
Obesity 0.68 (0.22, 2.07) 0.33 (0.06, 1.81)
Other neurological disorders 0.63 (0.29, 1.39) 0.33 (0.11, 0.95)*
Hypoglycemic event 0.56 (0.20, 1.53) 0.72 (0.22, 2.31)
Medical resource use, at least 1 visit
Inpatient 1.74 (1.12, 2.70)* 2.54 (1.49, 4.33)*
Outpatient 1.53 (0.45, 5.26) 1.76 (0.50, 6.17)
Number of primary care visits 0.88 (0.82, 0.96)* 0.94 (0.85, 1.05)
Non-insulin antihyperglycemic prescription drug use
Number of unique classes used 0.82 (0.69, 0.98)* 0.74 (0.58, 0.95)*
Any non-injectable drug 1.66 (0.84, 3.31) 0.44 (0.19, 1.02)
Any injectable drug 0.47 (0.20, 1.12) 0.67 (0.23, 1.98)
Any injectable drug includes amylin analogues and GLP-1 receptor agonists. Comorbidities with C3% prevalence in at least
one cohort during the baseline period were considered as potential predictors. The year of index date was also included
OR odds ratio, 95% CI 95% conﬁdence interval
* Statistically signiﬁcant at p\0.05
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[A] [B] [A vs. B] [C] [A vs. C]
Medical resource use, mean (SD) days
All-cause
Inpatient 2.2 (7.8) 4.9 (15.6) 0.004* 6.5 (17.6) 0.002*
Outpatient 23.9 (17.9) 23.4 (20.8) 0.755 23.0 (23.8) 0.657
T2DM-related
Inpatient 2.0 (7.3) 4.8 (15.2) 0.003* 6.3 (17.3) 0.002*
Outpatient 19.7 (15.1) 18.0 (17.2) 0.181 17.6 (18.1) 0.197
Hypoglycemia-related
Inpatient 0.0 (0.1) 0.1 (0.9) 0.125 0.1 (1.5) 0.321
Outpatient 0.1 (1.4) 0.2 (1.2) 0.553 0.2 (1.3) 0.843
Prescription drug use
Premixed and non-basal insulin use
At least one prescription
ﬁll, %
35.5 31.0 0.229 14.9 \0.001*
Premixed 14.2 7.1 0.003* 3.1 \0.001*
Non-basal 23.6 27.7 0.239 12.1 0.002*




2.4 (1.3) 2.3 (1.4) 0.401 2.6 (1.2) 0.075




94.4 84.7 \0.001* 94.5 0.943
Any injectable 0.8 3.4 0.024* 12.4 \0.001*
Healthcare costs, mean (SD)
All-cause
Total ¥707,463 (¥851,757) ¥766,740 (¥994,452) 0.414 ¥757,173 (¥1,299,368) 0.648
Medical costs ¥549,060 (¥837,214) ¥632,439 (¥939,071) 0.233 ¥635,580 (¥1,291,171) 0.424
Hospital costs ¥132,013 (¥566,539) ¥225,745 (¥667,162) 0.054 ¥320,582 (¥1,112,533) 0.036*
Outpatient costs ¥417,046 (¥470,183) ¥406,693 (¥497,763) 0.787 ¥314,998 (¥470,169) 0.022*
Pharmacy costs ¥158,403 (¥138,742) ¥134,301 (¥154,619) 0.039* ¥121,593 (¥114,203) 0.002*
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vs. ¥225,745 for interrupters and ¥320,582 for
discontinuers). However, continuers had higher
outpatient costs (¥417,046 vs. ¥406,693 for
interrupters and ¥314,998 for discontinuers)
and pharmacy costs (¥158,403 vs. ¥134,301 for
interrupters and ¥121,593 for discontinuers).
All comparisons (other than for outpatient costs
vs. interrupters) were statistically significant
(p\0.05). As a result, the three cohorts had
similar total (i.e., medical plus pharmacy) costs
in the year after insulin initiation (Table 3).
In terms of T2DM-related resource use,
continuers had fewer days hospitalized than
interrupters and discontinuers (2.0 ± 7.3 vs.
4.8 ± 15.2 for interrupters and 6.3 ± 17.3 for
discontinuers); whereas, the days with an
outpatient visit were similar across the three
cohorts. With regards to antihyperglycemic
medications, continuers were more likely to
use premixed insulin medications, but less
likely to use non-insulin
injectable medications (i.e., GLP-1 receptor
agonists) than the other two cohorts (Table 3).
The rates of other antihyperglycemic
medication use were similar between
continuers and discontinuers, but lower
among interrupters. As a result, similar to
the all-cause cost results, continuers had
similar T2DM-related total and medical costs
but had higher pharmacy costs compared to
the other two cohorts (Table 3). The finding
that the T2DM-related resource use and costs
are very similar to the overall resource use and
costs suggests that for all the three cohorts,
the majority of the estimated all-cause
resource use and costs in the year after basal










[A] [B] [A vs. B] [C] [A vs. C]
T2DM-related
Total ¥577,553 (¥762,676) ¥649,314 (¥895,614) 0.271 ¥644,783 (¥1,254,836) 0.517
Medical costs ¥490,373 (¥768,449) ¥584,741 (¥900,552) 0.151 ¥577,230 (¥1,261,781) 0.406
Hospital costs ¥112,697 (¥486,140) ¥213,618 (¥631,798) 0.022* ¥304,159 (¥1,102,136) 0.029*
Outpatient costs ¥377,677 (¥453,089) ¥371,124 (¥493,798) 0.861 ¥273,070 (¥460,546) 0.016*
Pharmacy costs ¥87,180 (¥70,813) ¥64,572 (¥60,112) \0.001* ¥67,553 (¥66,154) 0.003*
P values estimated relative to continuers cohort using weighted Chi-squared tests for categorical variables and weighted t
tests for continuous variables. Weights were estimated as the inverse of propensity scores. Propensity scores were estimated
among the full sample of continuers, interrupters, and discontinuers using a multinomial logistic regression that accounted
for observed differences in demographics, index basal insulin (type and mode of delivery), year of index date, select baseline
comorbidities, Charlson comorbidity index, select non-insulin antidiabetic and other prescription drug use in baseline,
inpatient resource use in baseline (at least one visit), and baseline costs; Hypoglycemia-related claims include those associated
with one or more of the following ICD-10 codes: E1x.0, E15.x, E16.x; T2DM-related medical claims include those
associated with one or more of the following ICD-10 codes: E11.x and E14.x; Any injectable includes amylin analogues and
GLP-1 receptor agonists; T2DM-related costs include medical costs associated with T2DM-related medical claims and
pharmacy costs for antihyperglycemic medications
SD standard deviation
* Statistically signiﬁcant at p\0.05
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Medication Use During the First Gap
During the first gap, the majority of interrupters
and discontinuers used at least one
antihyperglycemic medication. Specifically,
approximately 19% of the interrupters and
12% of discontinuers used a non-basal (i.e.,
mealtime) insulin, 1% of the interrupters and
10% of the discontinuers used non-insulin
injectable medications (i.e., GLP-1 receptor
agonists), and 74% of interrupters and 79% of
discontinuers used oral antihyperglycemic
medications during the gap (Table S2 in the
supplementary material).
Sensitivity Analyses
Results of the sensitivity analyses suggest that
the proportions of people characterized as
continuers or interrupters/discontinuers during
the first year after treatment initiation depend,
to a great extent, on the length of allowable
gaps in basal insulin use. Allowing for 60-day
gaps in basal insulin use would characterize
59% of patients as continuers, 16% as
interrupters, and 25% as discontinuers
(Table S3 in the supplementary material). Not
surprisingly, the persistence rates increase even
further when extending the gap length to
90 days (68%) and 120 days (73%). Allowing
for gaps shorter than the 90th percentile of days
between two consecutive prescription fills
during the first year after basal insulin
initiation would characterize 31% of the
sample as continuers, 49% as interrupters, and
20% as discontinuers (Table S3 in the
supplementary material). The resulting
proportions are similar to the core analyses,
suggesting a high degree of concordance
between the two definitions of persistence
within this population.
DISCUSSION
In this study, the majority of people with T2DM
who initiated basal insulin either used it
intermittently (42%) or discontinued (22%)
within the first year of treatment initiation,
with approximately half doing so within the
first 90 days of beginning therapy. The
proportions of patients classified as
discontinuers remained fairly similar across
the different definitions of persistence,
suggesting that discontinuation of basal
insulin treatment may occur shortly after
treatment initiation. Hospital visits and using
fewer other antihyperglycemic medications
during baseline were associated with
significantly higher likelihoods of treatment
interruption and discontinuation. During the
year after treatment initiation, the interrupters
and discontinuers had significantly more days
hospitalized, mainly attributable to T2DM, than
continuers. Relatedly, continuers had lower
hospital-related costs (potentially owing to
reduced likelihood of worsening of T2DM and
related comorbidities), but higher outpatient
and pharmacy costs (potentially associated with
continuous medication use and increased
interactions with their GPs). Taken together,
these components resulted in total medical
costs that were similar across the three
cohorts. In terms of antihyperglycemic
medications, the majority of interrupters and
discontinuers used non-basal
antihyperglycemic medications during the gap
in basal insulin treatment. In fact, during the
year after basal insulin initiation, greater
proportions of interrupters and discontinuers
(compared to continuers) used GLP-1 receptor
agonists. These findings suggest that for some
patients, an interruption or discontinuation of
basal insulin treatment may reflect a change in
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treatment regimen, e.g., from basal insulin to a
GLP-1 receptor agonist to manage their
condition. Future research should evaluate the
sequence of medications used by T2DM patients
in order to manage glycemic control and assess
reasons for interruption and discontinuation in
basal insulin treatment.
To the best of our knowledge, this is the first
study to assess persistence to basal insulin
therapy and implications thereof, using
real-world health insurance data in Japan.
Even so, aspects of our findings are similar to
studies conducted in other countries. For
example, similar to studies conducted in the
USA, we find that the majority of patients
interrupt or discontinue basal insulin
treatment during the year after initiation
[6–8]. Similarly, our finding that using
multiple antihyperglycemic medications before
insulin initiation is associated with a
significantly higher likelihood of continuing
basal insulin in the year after initiation, while
having a hospital visit before insulin initiation
is associated with a significantly lower
likelihood of insulin continuation is in line
with the findings reported in the literature
[6, 15]. The association between use of
multiple antihyperglycemic medications prior
to insulin initiation and greater persistence
could likely be explained by better awareness
regarding benefits of achieving glycemic
control. Another explanation could stem from
the fact that persistent users (i.e., continuers)
had higher medication use and lower
comorbidity rates as well as medical resource
use prior to basal insulin initiation, all of which
suggest that these patients may generally be
more likely to adhere to treatment regimens.
Future research should evaluate the association
between basal insulin persistence and
self-reported factors such as patient education
and adherence to other medications.
Several studies have evaluated the economic
consequences associated with insulin
non-persistence in other countries; however,
to the best of our knowledge this is the first
study to report similar findings among the
Japanese population. Our results take on
added importance as we find that continuers
had fewer days hospitalized and therefore had
lower medical costs during the follow-up
period, compared with both interrupters and
discontinuers (Table 3). While we did not
compare the results between interrupters and
discontinuers, the study findings are consistent
with results reported by Perez-Nieves et al. using
data from the USA [6] and provide important
insight regarding the significance of basal
insulin persistence. In particular, our findings
suggest that any interruption in treatment, even
if subsequently reinitiated, is associated with
outcomes requiring more acute care, and hence
emphasize the importance of patients staying
on therapy. However, further research is needed
to understand the specific mechanisms behind
the association between resource use and costs
and persistence to basal insulin, and to better
understand the differences within
non-persistent patients by comparing the
groups of interrupters and discontinuers.
This study has some limitations. First, the
analyses relied on accuracy and completeness of
administrative claims data for identifying
people with T2DM as well as assessing baseline
characteristics and outcomes. Second, clinical
information about diagnosis or severity of
illness (e.g., based on glycemic control) was
not captured in the data. Therefore, the
relationship between clinical measures such as
glycemic control and basal insulin persistence
in this study population remains unknown.
Relatedly, increased acute care events may also
be associated with increased work-loss costs.
However, these metrics were not available in
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the data and therefore do not count towards the
estimated burden associated with
non-persistence. Third, persistence patterns
were assessed on the basis of information
regarding dispensed medications as opposed to
actual observance of medications taken. In
addition, neither days’ supply nor dose of
insulin was reported on the claims, and the
duration of insulin prescriptions were
approximated on the basis of the dates of
prescriptions, potentially resulting in
inaccurate estimates of actual days’ supply of
insulin. Fourth, as noted earlier, both patterns
of basal insulin use as well as factors associated
with treatment interruption and
discontinuation were based on the
information captured in the data and do not
reflect physician or patient preference on
changing course of therapy. Finally, prior
studies have noted that the average age of
insulin initiation in Japan was 60 years
[22, 23]; however, the database does not
capture information about people aged
70 years or more. As such, the results are
limited to people aged less than 70 years with
employer-sponsored insurance in Japan and
may not generalize to other populations (e.g.,
older people, those who are unemployed).
CONCLUSIONS
The study findings indicate that the vast
majority of people initiating basal insulin in
Japan either interrupt or discontinue treatment
in the year after initiation (largely within the
first 90 days), which is associated with increased
medical resource use and costs during the year
after initiation. In addition, we find that
comorbidity profile, use of other
antihyperglycemic medications, and medical
resource use prior to treatment initiation are
significantly associated with patterns of basal
insulin use in the year after initiation. Further
research is necessary to better understand the
reasons why patients continue, discontinue, or
interrupt their insulin therapy. In addition,
further studies are needed to understand
specific mechanisms behind insulin
persistence and its implications to help
clinicians manage care for T2DM more
effectively.
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